Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lynozyfic
Pharma
ASH: Regeneron eyes simpler regimens to grow bispecifics' reach
Regeneron is proposing less onerous regimens in its bid to move T-cell engagers Lynozyfic and Ordspono into earlier lines of blood cancer treatment.
Angus Liu
Dec 8, 2025 8:00am
Regeneron snags FDA nod for myeloma bispecific Lynozyfic
Jul 2, 2025 11:29am
After FDA rejection, Regeneron scores EU nod for Lynozyfic
Apr 28, 2025 10:12am
